- Open Access
Histoplasma capsulatum yeast phase-specific protein Yps3p induces Toll-like receptor 2 signaling
© Aravalli et al; licensee BioMed Central Ltd. 2008
Received: 05 February 2008
Accepted: 07 July 2008
Published: 07 July 2008
Histoplasma capsulatum is a common cause of fungal infection in certain geographic areas, and although most infections are asymptomatic, it is capable of causing histoplasmosis, a disseminated, life-threatening disease, especially in immunocompromised individuals. A deeper understanding of this host-pathogen interaction is needed to develop novel therapeutic strategies to counter lethal infection. Although several lines of evidence suggest that this fungus is neurotropic in HIV patients, little is known about the immunobiology of Histoplasma infection in the central nervous system [CNS]. The goal of the present study was to understand the innate neuroimmune mechanisms that recognize H. capsulatum during the initial stages of infection. Using a 293T stable cell line expressing murine Toll-like receptor 2 [TLR2], we show here that TLR2 recognizes H. capsulatum cell wall protein Yps3p and induces the activation of NF-κB. In further experiments, we tested the ability of Yps3p to induce signaling from TLR2 in primary microglial cells, the resident brain macrophages of the CNS. Our data show that H. capsulatum Yps3p induced TLR2 signaling in wild-type microglia, but not in microglia isolated from TLR2 KO mice, confirming that Yps3p is a ligand for TLR2. Furthermore, Yps3p-induced TLR2 signaling was suppressed by vaccinia virus-encoded TLR inhibitors. This is the first demonstration of a fungal protein serving as a TLR ligand and mediating signaling in primary brain cells.
Inhalation of the human pathogenic fungus Histoplasma capsulatum may result in histoplasmosis, an important emerging infectious disease that occurs in immunocompromised individuals and transplant patients . Among the known varieties of this opportunistic fungus, H. capsulatum var capsulatum [referred hereafter as H. capsulatum] is present mostly in North and Central America, whereas H. capsulatum var. duboisii is endemic in Africa (reviewed in ). Histoplasmosis has also been reported to occur in the central nervous system [CNS] [1, 3–5]. Current treatments for CNS histoplasmosis with amphotericin B combined with one of two commonly used azoles, fluoconazole and itraconazole, have not been encouraging [2, 6–8] although successful outcomes have been reported [7, 9, 10]. In some instances, histoplasmosis may manifest either as myelopathy or as brain tumor further complicating the diagnosis [11, 12]. Treatment with fluconazole in the mouse model of intracranial infection has been proved to be ineffective . Therefore, extensive efforts are being made to develop novel diagnostic tools and anti-fungal therapies to diagnose histoplasmosis and to curtail its progression.
H. capsulatum is a dimorphic fungus that exists as mycelium at 25°C and as yeast at 37°C . Conversion of mycelium to the yeast phase has been demonstrated to be critical for pathogenicity of the fungus as agents that inhibit the dimorphic transition, such as p-chloromercuriphenylsulfonic acid, render virulent H. capsulatum strains avirulent . Macrophages provide a protected environment for H. capsulatum to multiply and disseminate from the lungs to other organs. Initial studies with murine macrophages demonstrated that H. capsulatum could survive in the harsh conditions of phagolysosomal compartments  and modulate the pH of its intracellular niche . This fungus was later shown to survive in 'modified' lysosomes in human macrophages, as well in the RAW264.7 cell line .
Toll-like receptors [TLRs] are a class of pathogen-recognition receptors that recognize specific molecular patterns [PAMPs] on the surface of invading pathogens and generate innate immune responses to counter infection . Microglia have been shown to express mRNAs for all known TLRs , and recent reports demonstrate that TLR2 on microglial cells recognizes a number of PAMPs and triggers immune responses [20–22]. A critical role for TLRs in recognizing and triggering innate immune responses against several opportunistic fungal pathogens such as Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans have been reported [23–32]. In contrast to these organisms, little is known about the involvement of TLRs in host responses to dimorphic fungi such as H. capsulatum, Coccidiodes immitis, Blastomyces dermatitidis and Paracoccoidioides brasiliensis. To date, fungal cell wall and capsule components such as phospholipomannan and zymosan were reported to be ligands for a number of cellular receptors, including the TLRs, but specific fungal proteins that could induce signaling from these receptors have not yet been identified.
Several H. capsulatum genes have been found to be differentially expressed during phase transition, and one such gene YPS3 is induced within 2 h following the 25°C-to-37°C temperature shift . This yeast-phase-specific gene encodes the Yps3p protein that is localized to its cell wall and is also expressed as a secretory protein in infected cells [33, 34]. It has been proposed that Yps3p may have a regulatory role in fungal transition and may correlate with pathogenicity . Murine T cells recognize components from cell wall and cell membrane extracts of H. capsulatum , suggesting that fungal wall components are recognized by immune cells. In this study, we show for the first time that H. capsulatum cell membrane protein Yps3p triggers TLR2 signaling and leads to the activation of NF-κB in primary microglial cells.
Organism and culture conditions
H. capsulatum G217B [ATCC 26032] is a North American isolate of RFLP class 2 which was termed 'high level' in thermotolerance and pathogenicity. The fungus was grown in Histoplasma-macrophage medium (HMM) broth  in a 5% CO2-95% air atmosphere. Experiments were performed with H. capsulatum grown as yeast cells at 37°C.
Cloning, expression, and purification of recombinant fungal proteins
Recombinant Yps3p and H proteins was prepared as described previously [33, 37]. For the preparation of crude cell extract, fractionation was done as follows: log-phase yeast cells were pelleted by centrifugation, washed, and resuspended in PBS. They were then disrupted using glass beads in a Mini-Beadbeater-8 (Biospec Products, Bartlesville, OK) at highest setting for three 1 min periods, separated by chilling on ice for 1 min. Beads were removed by low-speed centrifugation and the cell lysate was spun at 15K RPM in a microcentrifuge at 4 C for 30 min. The supernatant was removed as the cytoplasmic fraction. The pellet was resuspended in PBS as the cell wall/membrane fraction.
Preparation of microglial cultures
Microglial cell cultures were purified from wild-type C57BL/6 and TLR2 KO mice (Jackson Laboratories, Bar Harbor, ME) using a method described previously with minor modifications . Briefly, cerebral cortical cells from 1-d-old mice were dissociated after a 30 min trypsinization [0.25%] and plated in 75-cm2 Falcon culture flask in DMEM (Sigma-Aldrich, St. Louis, MO) containing 10% heat-inactivated FBS (Hyclone Laboratories, Logan, UT)and penicillin/streptomycin (Sigma-Aldrich). The medium was replenished 1 and 4 d after plating. On d 8 of culture, flasks were shaken for 20 min at a speed of 180 rpm in an orbital shaker to remove unattached cells. On d 12 of culture, microglia floating in the media were collected by aspiration, pooled, centrifuged and seeded at appropriate densities after counting. The cells were washed twice with fresh medium 1 h after seeding to remove non-adherent cells. Microglia prepared this way stain 95–98% positive with Mac-1 antibody (Roche Applied Science, Indianapolis, IN).
Cloning of VV TLR inhibitors
DNA obtained from the VV Western Reserve strain was used to clone four viral gene products: A46R, A52R, N1L and K1L using PCR. Primers used for amplification were: A46R: Forward: 5'-CAT GCC ATG GCG TTT GAT ATC AGT-3' and Reverse: 5'-CAT GCC ATG GAT GGC GTT TGA TAT-3'; A52R: Forward: 5'-CAT GCC ATG GAC ATA AAG ATA GAT-3' and Reverse: 5'-GTG GAA ATG TCA TAG GCT AGC TAG-3'; N1L: Forward: 5'-CAG GTC ATG AGG ACT CTA CTT ATT-3' and Reverse: 5'-CTA GCT AGC TTA TTT TTC ACC ATA-3'; K1L: Forward: 5'-CAG GAT ATC ATG GAT CTG TCA CGA-3' and Reverse: 5'-CTA GCT AGC TTA GTT TTT CTT TAC AC-3'. PCR was performed on a Gradient 40 Robocycler (Stratagene, La Jolla, CA) using Pfu polymerase (Stratagene) with the following conditions: initial denaturation at 95°C for 2 min 30 sec, followed by 30 cycles of 95°C for 1 min, annealing at 60°C for 1 min and elongation at 72°C for 3 min. Following PCR amplification, viral gene products were purified using a 0.8% agarose gel and were cloned into pORF5-mIL10 (InvivoGen) by replacing the mIL-10 ORF with each VV ORF as described previously . This vector carries the murine IL-10 ORF under the control of a composite binary promoter comprised of the elongation factor 1α (EF-1α) and the 5' untranslated region of the human eukaryotic initiation factor 4 g (eIF-4 g). The expression vectors thus generated were termed pORF5-A46R, pORF5-A52R, pORF5-N1L and pORF5-K1L. Expression of these viral proteins was confirmed using Western blot analysis .
HEK293T cells, as well as wild-type and TLR2 KO microglia, were transfected with 1 μg pNiFty2-Luc plasmid (InvivoGen) expressing an NF-κB-driven firefly luciferase reporter gene. FuGene 6 was used for transfection of the 293T-mTLR2 cells. Primary microglia are post-mitotic cells which are extremely difficult to transfect using standard methods. In this study, they were successfully transfected using the mouse macrophage nucleofection kit (Amaxa Biosystems, Gaithersburg, MD) and the program Y-01 on the nucleofector I device (Amaxa). Although the transfection efficiency using nucleofection was still low (<10%), luciferase expression occured only in cells that took up the pNiFty2-Luc plasmid. Following nucleofection, the cells were plated in 12-well plates and incubated overnight at 37°C. To stimulate TLR2 signaling, 0.01% heat-killed L. monocytogenes (InvivoGen) was added to the culture medium for 5 h. The cells were then lysed and luciferase activity was measured using Bright-Glo luciferase assay substrate (Promega, Madison, WI) on the IVIS® Imaging System (Xenogen Corporation, Alameda, CA). Expression levels of the luciferase reported gene were quantified using Living Image® software (Xenogen). Tranfection efficiencies were tested using a control plasmid expressing green fluorescent protein under the control of CMV IE promoter and the values were normalized to the transfection efficiencies obtained.
A sandwich ELISA-based system was used to quantify CCL2 levels from WT and TLR2 KO murine microglial cell culture supernatants. ELISA plates were coated with rat-anti-mouse CCL2 capture antibodies (R&D Systems, Minneapolis, MN) at 1–2 μg/ml overnight at 4°C. The plates were washed (0.05% Tween-20 in phosphate-buffered saline, PBS) and blocked with 1% BSA in PBS for 1 h at 37°C. Detection antibodies (biotinylated goat anti-mouse CCL2 antibodies, 1–2 μg/ml; R&D Systems) were added for 90 min at room temperature followed by peroxidase conjugated strepavidin (1:3000; Jackson Immunoresearch) for 45 min. A chromogenic substrate (K-blue; Neogen Corporation, Lexington, KY) was then added and color development was stopped with 1 M H2SO4. Absorbance values at 450 nm were used to quantify chemokine levels based on the standard concentration curve generated from serial dilutions.
Histoplasma capsulatumprotein Yps3p is a ligand for Toll-like receptor 2
Vaccinia virus proteins inhibitors of TLR signaling blunt Yps3p-induced luciferase expression
TLR2 is required for Yps3p-induced activation of NF-κB in primary murine microglia
Airborne invasive fungal pathogens can cause morbidity and mortality in immunocompromised individuals, including those with HIV/AIDS. H. capsulatum is a major cause of respiratory infections worldwide and is the etiologic agent of histoplasmosis. In addition to respiratory infections, histoplasmosis has been reported to occur in the brain [1, 3–5]. In the present study, we showed that the interaction of H. capsulatum Yps3p with microglial cells leads to NF-κB activation via the TLR2 pathway, in both a stable cell line expressing murine TLR2 as well as in primary microglia.
Studies aimed at understanding the role of TLRs in fungal recognition have been controversial. While TLR2 has been shown to be essential for immune responses in macrophages , TLR2 KO mice were found to be resistant to candidiasis. It has been reported that both TLR2 and TLR4 are key cellular receptors that recognize opportunistic fungal pathogens such as C. albicans, A. fumigatus and C. neoformans. Phosholipomannan, a unique glycoprotein in the cell wall of C. albicans, is a ligand of TLR2, and when mouse macrophages are infected with C. albicans they activate NF-κB and produce TNF-α. [28, 40]. While TLR2 has been shown to be essential for defense against C. albicans , contrasting results were reported with TLR2 KO mice being resistant to candidiasis whereas TLR4 KO mice were susceptible [26, 27]. Both in vitro experiments using macrophages and transfected cell lines, as well as in vivo experiments with experiments using TLR-deficient mice infected with A. fumigatus, have suggested a role for TLR2 and TLR4 [23, 25, 31, 45]. Similarly, one study showed that TLR2 signaling was necessary for host defense against C. neoformans , while another reported limited involvement of TLR2 and TLR4 in response to C. neoformans infection .
In this study, we report for the first time that H. capsulatum triggers TLR2 signaling leading to NF-κB activation in microglial cells and that Yps3p protein is an important fungal component that induces TLR2 signaling. A deeper understanding of host-pathogen interactions will enable us to tackle new challenges posed by fungal pathogens and develop improved therapeutic measures to treat histoplasmosis as well as other deadly mycological diseases.
This research was supported in part by a grant from the Minnesota Medical Foundation. JPW received support from NIH R01 awards HL055949 and AI052303. We thank Megan Bohse and Kimber Munson for recombinant protein purification, and Prof. Phillip Peterson for his input.
- Anaissie E, Fainstein V, Samo T, Bodey GP, Sarosi GA: Central nervous system histoplasmosis. An unappreciated complication of the acquired immunodeficiency syndrome. Am J Med. 1988, 84: 215-217. 10.1016/0002-9343(88)90416-0.View ArticlePubMedGoogle Scholar
- Kauffman CA: Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. 2007, 20: 115-132. 10.1128/CMR.00027-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Tan V, Wilkins P, Badve S, Coppen M, Lucas S, Hay R, Schon F: Histoplasmosis of the central nervous system. J Neurol Neurosurg Psychiatry. 1992, 55: 619-622.PubMed CentralView ArticlePubMedGoogle Scholar
- Vos MJ, Debets-Ossenkopp YJ, Claessen FA, Hazenberg GJ, Heimans JJ: Cerebellar and medullar histoplasmosis. Neurology. 2000, 54: 1441.View ArticlePubMedGoogle Scholar
- Walsh TJ, Groll AH: Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis. 1999, 1: 247-261. 10.1034/j.1399-3062.1999.010404.x.View ArticlePubMedGoogle Scholar
- Haynes RR, Connolly PA, Durkin MM, LeMonte AM, Smedema ML, Brizendine E, Wheat LJ: Antifungal therapy for central nervous system histoplasmosis, using a newly developed intracranial model of infection. J Infect Dis. 2002, 185: 1830-1832. 10.1086/340825.View ArticlePubMedGoogle Scholar
- LeMonte AM, Washum KE, Smedema ML, Schnizlein-Bick C, Kohler SM, Wheat LJ: Amphotericin B combined with itraconazole or fluconazole for treatment of histoplasmosis. J Infect Dis. 2000, 182: 545-550. 10.1086/315717.View ArticlePubMedGoogle Scholar
- Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, Hecht GFM, Powderly W, AIDS Clinical Trial Group: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med. 1995, 98: 336-342. 10.1016/S0002-9343(99)80311-8.View ArticlePubMedGoogle Scholar
- Knapp S, Turnherr M, Dekan G, Willinger B, Stingl G, Rieger A: A case of HIV-associated cerebral histoplasmosis successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1999, 18: 658-661. 10.1007/s100960050368.View ArticlePubMedGoogle Scholar
- Tiraboschi I, Cases Parera I, Pikielny R, Scattini G, Michell F: Chronic Histoplasma capsulatum infection of the central nervous system successfully treated with fluconazole. Eur Neurol. 1992, 32: 70-73. 10.1159/000116794.View ArticlePubMedGoogle Scholar
- Klein CJ, Dinapoli RP, Temesgen Z, Meyer FB: Central nervous system histoplasmosis mimicking a brain tumor: difficulties in diagnosis and treatment. Mayo Clin Proc. 1999, 74: 803-807.View ArticlePubMedGoogle Scholar
- Voelker JL, Muller J, Worth RM: Intermedullary spinal Histoplasma granuloma: case report. J Neurosurg. 1989, 70: 959-961.View ArticlePubMedGoogle Scholar
- Keath EJ, Painter AA, Kobayashi GS, Medoff G: Variable expression of a yeast-phase-specific gene in Histoplasma capsulatum strains differing in thermotolerance and virulence. Infect Immun. 1989, 57: 1384-1390.PubMed CentralPubMedGoogle Scholar
- Medoff G, Sacco M, Maresca B, Schlessinger D, Painter A, Kobayashi GS, Carratu L: Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum. Science. 1986, 231: 476-479. 10.1126/science.3001938.View ArticlePubMedGoogle Scholar
- Eissenberg LG, Goldman WE, Schlesinger PH: Histoplasma capsulatum modulates the acidification of phagolysosomes. J Exp Med. 1993, 177: 1605-1611. 10.1084/jem.177.6.1605.View ArticlePubMedGoogle Scholar
- Eissenberg LG, Schlesinger PH, Goldman WE: Phagosome-lysosome fusion in P388D1 macrophages infected with Histoplasma capsulatum. J Leukoc Biol. 1988, 43: 483-491.PubMedGoogle Scholar
- Strasser JE, Newman SL, Ciraolo GM, Morris RE, Howell ML, Dean GE: Regulation of the macrophage vacuolar ATPase and phagosome-lysosome fusion by Histoplasma capsulatum. J Immunol. 1999, 162: 6148-6154.PubMedGoogle Scholar
- Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801. 10.1016/j.cell.2006.02.015.View ArticlePubMedGoogle Scholar
- Aravalli RN, Peterson PK, Lokensgard JR: Toll-like receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol. 2007, 2: 291-302. 10.1007/s11481-007-9071-5.View ArticleGoogle Scholar
- Aravalli RN, Hu S, Rowen TN, Palmquist J, Lokensgard JR: Cutting Edge: TLR2-mediated production of proinflammatory cytokines and chemokines by microglial cells in response to herpes simplex virus. J Immunol. 2005, 175: 4189-4173.View ArticlePubMedGoogle Scholar
- Kielian T, Esen N, Bearden ED: Toll-like receptor 2 (TLR2) is pivotal for recognition of S. aureus peptidoglycan but not intact bacteria by microglia. Glia. 2005, 49: 567-576. 10.1002/glia.20144.PubMed CentralView ArticlePubMedGoogle Scholar
- Kinsner A, Boveri M, Hareng L, Brown GC, Coecke S, Hartung T, Bal-Price A: Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide. J Neurochem. 2006, 99: 596-607. 10.1111/j.1471-4159.2006.04085.x.View ArticlePubMedGoogle Scholar
- Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L: The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol. 2004, 172: 3059-3069.View ArticlePubMedGoogle Scholar
- Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, Catania MR, Bombaci M, Beninati C, Teti G, Mancuso G: MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans. Eur J Immunol. 2005, 35: 870-878. 10.1002/eji.200425799.View ArticlePubMedGoogle Scholar
- Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM: Toll-like receptor [TLR] signaling in response to Aspergillus fumigatus. J Biol Chem. 2002, 277: 39320-39326. 10.1074/jbc.M201683200.View ArticlePubMedGoogle Scholar
- Netea MG, Sutmuller R, Hermann C, Graaf Van der CA, Meer Van der JW, van Krieken JH, Hartung T, Adema G, Kullberg BJ: Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol. 2004, 172: 3712-3718.View ArticlePubMedGoogle Scholar
- Netea MG, Graaf Van Der CA, Vonk AG, Verschueren I, Meer Van Der JW, Kullberg BJ: The role of toll-like receptor [TLR] 2 and TLR4 in the host defense against disseminated candidiasis. J Infect Dis. 2002, 185: 1483-1489. 10.1086/340511.View ArticlePubMedGoogle Scholar
- Roeder A, Kirschning CJ, Schaller M, Weindl G, Wagner H, Korting HC, Rupec RA: Induction of nuclear factor-kappaB and c-Jun/activator protein-1 via toll-like receptor 2 in macrophages by antimycotic-treated Candida albicans. J Infect Dis. 2004, 190: 1318-1326. 10.1086/423854.View ArticlePubMedGoogle Scholar
- Tada H, Nemoto E, Shimauchi H, Watanabe T, Mikami T, Matsumoto T, Ohno N, Tamura H, Shibata K, Akashi S, Miyake K, Sugawara S, Takada H: Saccharomyces cerevisiae – and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol Immunol. 2002, 46: 503-512.View ArticlePubMedGoogle Scholar
- Villamon E, Gozalbo D, Roig P, O'Connor JE, Fradelizi D, Gil ML: Toll-like receptor-2 is essential in murine defenses against Candida albicans infections. Microbes Infect. 2004, 6: 1-7. 10.1016/j.micinf.2003.09.020.View ArticlePubMedGoogle Scholar
- Balloy V, Si-Tahar M, Takeuchi O, Philippe B, Nahori MA, Tanguy M, Huerre M, Akira S, Latge JP, Chignard M: Involvement of toll-like receptor 2 in experimental invasive pulmonary aspergillosis. Infect Immun. 2005, 73: 5420-5425. 10.1128/IAI.73.9.5420-5425.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakamura K, Miyagi K, Koguchi Y, Kinjo Y, Uezu K, Kinjo T, Akamine M, Fujita J, Kawamura I, Mitsuyama M, Adachi Y, Ohno N, Takeda K, Akira S, Miyazato A, Kaku M, Kawakami K: Limited contribution of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus neoformans. FEMS Immunol Med Microbiol. 2006, 47: 148-154. 10.1111/j.1574-695X.2006.00078.x.View ArticlePubMedGoogle Scholar
- Bohse ML, Woods JP: Surface localization of the Yps3p protein of Histoplasma capsulatum. Eukaryot Cell. 2005, 4: 685-693. 10.1128/EC.4.4.685-693.2005.PubMed CentralView ArticlePubMedGoogle Scholar
- Weaver CH, Sheehan KC, Keath EJ: Localization of a yeast-phase-specific gene product to the cell wall in Histoplasma capsulatum. Infect Immun. 1996, 64: 3048-3054.PubMed CentralPubMedGoogle Scholar
- Henderson HM, Deepe GS: Recognition of Histoplasma capsulatum yeast-cell antigens by human lymphocytes and human T-cell clones. J Leukoc Biol. 1992, 51: 432-436.PubMedGoogle Scholar
- Woods JP, Heinecke EL, Goldman WE: Electrotransformation and expression of bacterial genes encoding hygromycin phosphotransferase and beta-galactosidase in the pathogenic fungus Histoplasma capsulatum. Infect Immun. 1998, 66: 1697-1707.PubMed CentralPubMedGoogle Scholar
- Fisher KL, Woods JP: Determination of β-glucosidase enzymatic function of the Histoplasma capsulatum H antigen using a native expression system. Gene. 2000, 247: 191-197. 10.1016/S0378-1119(00)00099-8.View ArticlePubMedGoogle Scholar
- Chao CC, Molitor TW, Hu S: Neuroprotective role of IL-4 against activated microglia. J Immunol. 1993, 151: 1473-1481.PubMedGoogle Scholar
- Aravalli RN, Hu S, Lokensgard JR: Inhibition of Toll-like receptor signaling in primary murine microglia. J Neuroimmune Pharmacol. 2008, 3: 5-11. 10.1007/s11481-007-9097-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Jouault T, Ibata-Ombetta S, Takeuchi O, Trinel PA, Sacchetti P, Lefebvre P, Akira S, Poulain D: Candida albicans phospholipomannan is sensed through toll-like receptors. J Infect Dis. 2003, 188: 165-172. 10.1086/375784.View ArticlePubMedGoogle Scholar
- Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA: A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA. 2000, 97: 10162-10167. 10.1073/pnas.160027697.PubMed CentralView ArticlePubMedGoogle Scholar
- Harte MT, Haga IR, Maloney G, Gray P, Reading PC, Bartlett NW, Smith GL, Bowie A, O'Neill LA: The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med. 2003, 197: 343-351. 10.1084/jem.20021652.PubMed CentralView ArticlePubMedGoogle Scholar
- DiPerna G, Stack J, Bowie AG, Boyd A, Kotwal G, Zhang Z, Arvikar S, Latz E, Fitzgerald KA, Marshall WL: Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem. 2004, 279: 36570-36578. 10.1074/jbc.M400567200.View ArticlePubMedGoogle Scholar
- Shisler JL, Jin XL: The vaccinia virus K1L gene product inhibits host NF-κB activation by preventing IκBα degradation. J Virol. 2004, 78: 3553-3560. 10.1128/JVI.78.7.3553-3560.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Meier A, Kirschning CJ, Nikolaus T, Wagner H, Heesemann J, Ebel F: Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol. 2003, 5: 561-570. 10.1046/j.1462-5822.2003.00301.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.